未登录First-in-Human Study of the PARP Inhibitor HWH340 in Advanced Solid Tumors with Enrichment for Homologous Recombination Repair Gene MutationsHWH340 PARP抑制剂在富集同源重组修复基因突变的晚期实体瘤中的首次人体研究
Zhang, Jie; Wang, Xiaojia; Xu, Huiting; Zang, Aimin; Zhao, Jun; Chen, Jinping; Lei, Ruiwen; Zhang, Zhen; Hao, Chunfang; Liu, Yunpeng; Zhou, Rongwei; He, Lijia; Sun, Tao; Ouyang, Quchang; Chen, Sheng; Xu, Jingqiao; Zhou, Wei; Shi, Yehui; Tong, Zhongsheng .png)
分享.png)
收藏分享 收藏 分享 收藏 分享 收藏 分享 收藏 First-in-human study of DP303c, a HER2-targeted antibody-drug conjugate in patients with HER2 positive solid tumorsZhang, Jian; Du, Yiqun; Meng, Yanchun; Liu, Xiaojun; Mu, Yuxin; Liu, Yunpeng; Shi, Yehui; Wang, Jufeng; Zang, Aimin; Gu, Shanzhi; Liu, Tianshu; Zhou, Huan; Guo, Hongqian; Xiang, Silong; Zhang, Xialu; Wu, Suqiong; Qi, Huanhuan; Li, Mengke; Hu, Xichun 分享 收藏 Phase 1a study of ESG401, a Trop2 antibody-drug conjugate, in patients with locally advanced/metastatic solid tumorsWang, Jiani; Tong, Zhongsheng; Tan, Yinuo; Shi, Yehui; Wu, Yun; Zhou, Qing; Xing, Xiaoyan; Chen, Xiaomei; Qiu, Fuming; Ma, Fei 分享 收藏 Combination Therapy of Pyrotinib and Metronomic Vinorelbine in HER2+Advanced Breast Cancer after Trastuzumab Failure (PROVE): A Prospective Phase 2 StudyPyrotinib与常规剂量长春瑞滨联合疗法在曲妥珠单抗治疗失败的HER2阳性晚期乳腺癌中的疗效研究（PROVE）：一项前瞻性II期临床试验Hao, Chunfang; Wang, Xu; Shi, Yehui; Tong, Zhongsheng; Li, Shufen; Liu, Xiaodong; Zhang, Lan; Zhang, Jie; Meng, Wenjing; Zhang, Li 分享 收藏 分享 收藏 分享 收藏 A first-in-human phase 1 study of SIM0270, a brain-penetrant oral selective estrogen receptor degrader (SERD), in patients with ER+/HER2-locally advanced or metastatic breast cancerWu, Jiong; Zhang, Jian; Zhang, Qingyuan; Sun, Yuping; Li, Hongtao; Yin, Yongmei; Shi, Yehui; Li, Wenfeng; Liu, Yunjiang; Yan, Min; Yang, Chen; Zhu, Lili; Yang, Yang; Xue, Liting 分享 收藏 Camrelizumab in Combination with Nab-Paclitaxel and Carboplatin versus Nab-Paclitaxel and Carboplatin as Neoadjuvant Therapy for Triple Negative Breast Cancer: A Multicenter, Open-Label, Randomized Controlled StudyZhao, Weipeng; Wang, Xin; Zhang, Bin; Shi, Yehui; Wang, Chen; Wang, Xu; Li, Shufen; Hao, Chunfang; Lu, Ning; Jia, Yongsheng; Zhang, Li; Zhang, Lan; Sun, Weixin; Cao, Xuchen; Tong, Zhongsheng 分享 收藏 Report on Cohort Expansion of Phase I Study to Investigate the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of BB-1701 in Patients with Locally Advanced/Metastatic HER2 Low Breast CancerMa, Fei; Munster, Pamela; Guan, Xiaoxiang; Wang, Jingfen; Yao, Herui; Hamilton, Erika; Wang, Xian; Shi, Yehui; Liang, Xinjun; Xu, Nong; Tang, Huoling; Zhou, Yuhong; Wei, Ziping 分享 收藏 Inetetamab combined with sirolimus and chemotherapy in HER2 positive metastatic breast cancer patients with abnormal activation of Pi3k/Akt/mTOR pathway after trastuzumab treatmentLi, Qiao; Lv, Dan; Sun, Xiaoying; Wang, Mengyuan; Cai, Li; Liu, Feng; Li, Chenghui; Zhao, Jiuda; Sun, Jing; Shi, Yehui; Ma, Fei 分享 收藏 分享 收藏 Effective anti-diarrhea strategies for pyrotinib (PYR) plus trastuzumab (H) and docetaxel (T) in patients ( pts) with HER2+metastatic breast cancer (mBC): a multicenter, phase 1 trial (PHAENNA)Yao, H.; Shi, Y.; Yao, Y.; Li, H.; Zhou, H.; Wang, S.; Qin, Q.; Li, W.; Geng, C.; Wang, M.; Wang, X.; Cao, Y.; Yu, Z.; Du, C.; Zhao, W.; Wu, S.; Cui, Y.; Liu, P.; Lin, J.; Song, E. 分享 收藏 分享 收藏 Initial results from 2 Phase I studies of NMS-03305293, a selective PARP1 inhibitorGeurts, Marjolein; Gramatzki, Dorothee; Merler, Sara; Duca, Matteo; Girardi, Fabio; Sener, Ugur T.; Roberti, Domenico; Saturno, Grazia; Crivori, Patrizia; Montagnoli, Alessia; Mahnke, Lisa; Fu, Siqing; Gaviani, Paola; Jaeckle, Kurt A.; Zhang, Jian; Shi, Yehui; Guarneri, Valentina; Weller, Michael; Kizilbash, Sani H.; van den Bent, Martin J.; Milella, Michele; Damian, Silvia 分享 收藏 Pharmacokinetics, pharmacodynamics and efficacy of pemigatinib (a selective inhibitor of fibroblast growth factor receptor 1-3) monotherapy in Chinese patients with advanced solid tumors: a phase i clinical trialDeng, Ting; Zhang, Le; Shi, Yehui; Bai, Guiying; Pan, Yueyin; Shen, Aizong; Han, Xinghua; Yang, Zhaoyi; Chen, Mingxia; Zhou, Hui; Luo, Yang; Zheng, Shirui; Ba, Yi 分享 收藏 A multicenter, open-label, dose escalation and expansion study of DP303c in patients with HER2-positive pre-treated advanced solid tumorsZhang, J.; Hu, X.; Du, Y.; Meng, Y.; Liu, Y.; Shi, Y.; Wang, J.; Zang, A.; Gu, S.; Liu, T.; Zhou, H.; Guo, H.; Xiang, S.; Zhang, X.; Wu, S.; Li, M. 分享 收藏 
.png){kind=icon}
.png){kind=icon}
.png){kind=icon}
.png){kind=icon}
